Curis (NASDAQ:CRIS) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.22) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.31) by $0.09, MarketWatch Earnings reports. Curis had a negative return on equity of 225.77% and a negative net margin of 407.29%. The company had revenue of $2.85 million for the quarter, compared to the consensus estimate of $2.38 million.
NASDAQ:CRIS opened at $1.72 on Friday. Curis has a 1 year low of $1.36 and a 1 year high of $7.90. The company has a current ratio of 3.01, a quick ratio of 3.01 and a debt-to-equity ratio of 4.43.
Several brokerages have weighed in on CRIS. Cowen restated a “buy” rating on shares of Curis in a report on Monday, August 6th. SunTrust Banks lowered their price objective on Curis to $8.00 and set a “buy” rating for the company in a research report on Friday, August 3rd. Finally, Zacks Investment Research raised Curis from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a research report on Wednesday, August 8th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $13.33.
Several large investors have recently added to or reduced their stakes in the company. Millennium Management LLC acquired a new position in shares of Curis during the 2nd quarter worth about $540,000. Paloma Partners Management Co acquired a new position in shares of Curis during the 2nd quarter worth about $223,000. Finally, LMR Partners LLP acquired a new position in shares of Curis during the 2nd quarter worth about $124,000. 33.51% of the stock is owned by institutional investors and hedge funds.
Curis Company Profile
Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.
Further Reading: Can individual investors take part in an IPO?
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.